Pet Pharm Biotech Balance Sheet

Financials in millions TWD. Fiscal year is January - December.

Millions TWD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Cash & Equivalents	181.79	168.49	16.76
Cash & Short-Term Investments	181.79	168.49	16.76
Cash Growth	7.89%	905.52%	-
Receivables	33.78	31.24	20.91
Inventory	13.68	10.8	5.81
Other Current Assets	212.69	143.88	54.84
Total Current Assets	441.93	354.4	98.31
Property, Plant & Equipment	290.2	92.45	84.57
Other Intangible Assets	9.08	4.05	5.08
Long-Term Deferred Tax Assets	2.09	-	-
Other Long-Term Assets	16.76	36.67	3.93
Total Assets	760.06	487.58	191.89
Accounts Payable	7.92	4.81	2.91
Current Portion of Leases	6.42	6.57	4.58
Current Unearned Revenue	4.31	3.94	3.09
Other Current Liabilities	121.41	16.99	8.88
Total Current Liabilities	140.05	32.31	19.46
Long-Term Leases	37.46	41.63	37.94
Total Liabilities	177.52	73.94	57.4
Common Stock	405.29	371.9	251.9
Additional Paid-In Capital	78.72	150.01	-
Retained Earnings	14.51	-108.27	-117.42
Comprehensive Income & Other	84.03	-	-
Shareholders' Equity	582.54	413.64	134.48
Total Liabilities & Equity	760.06	487.58	191.89
Total Debt	43.88	48.2	42.52
Net Cash (Debt)	137.91	120.29	-25.77
Net Cash Growth	14.65%	-	-
Net Cash Per Share	3.42	4.08	-1.08
Filing Date Shares Outstanding	40.29	29.51	23.81
Total Common Shares Outstanding	40.29	29.51	23.81
Working Capital	301.88	322.1	78.85
Book Value Per Share	14.46	14.02	5.65
Tangible Book Value	573.47	409.59	129.4
Tangible Book Value Per Share	14.23	13.88	5.43

Source: S&P Global Market Intelligence. Standard template. Financial Sources.